Cytokinetics (NASDAQ:CYTK) Price Target Cut to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective decreased by Raymond James from $92.00 to $70.00 in a research note released on Thursday, Benzinga reports. Raymond James currently has an outperform rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Truist Financial reissued a buy rating and […]

Related Keywords

,Fady Ibraham Malik ,Raymond James ,Johnt Henderson ,Victory Capital Management Inc ,Vanguard Group Inc ,Cytokinetics Company Profile ,Needham Company ,Legato Capital Management ,Cytokinetics Incorporated ,Free Report ,Moderate Buy ,Get Free Report ,Ibraham Malik ,Director John ,Minvest Partners ,Capital Management ,Victory Capital Management ,Cytokinetics Daily ,